Invex Therapeutics has broadened its preclinical Alzheimer's program with Tessara Therapeutics, while its cash reserves dipped to $4.02 million in Q4 FY26 amid increased research and administrative costs.
- Expanded preclinical program targets Alzheimer's with Exenatide combinations
- Focus on neuroprotection and ferroptosis mechanisms in AD model
- Cash reserves declined to $4.02 million from $4.52 million
- Operating cash outflows rose to $501,000, driven by R&D and admin costs
- Payments to related parties totalled $54,000 for the quarter
Expanded Alzheimer's Research Focus with Tessara Therapeutics
Invex Therapeutics Ltd (ASX:IXC) has intensified its preclinical research efforts, advancing its evaluation of Exenatide and other GLP-1 receptor agonists in collaboration with Tessara Therapeutics. The expanded program, building on prior findings, uses Tessara's ADBrain™ human induced pluripotent stem cell-derived Alzheimer's disease model to benchmark Exenatide against a current GLP-1 agonist and explore novel combination regimens.
The research notably targets ferroptosis, an iron-dependent oxidative cell death pathway implicated in Alzheimer’s neurodegeneration, where Exenatide has shown potential neuroprotective effects. The study aims to assess additive or synergistic benefits over existing symptomatic treatments, including combinations with naturally occurring factors that may enhance therapeutic outcomes.
Financial Position Reflects Increased Research and Administrative Activity
Invex ended the June quarter with $4.02 million in cash and cash equivalents, down from $4.52 million at the previous quarter’s end. Operating cash outflows rose sharply to $501,000, compared to $79,000 in Q3 FY26, primarily due to an expanded research program and higher corporate costs.
Research and development expenditure surged to $379,000 for the quarter, a significant jump from $53,000 in the prior period, reflecting the ramp-up in preclinical activities with Tessara. Meanwhile, administration and corporate costs doubled to $135,000, largely driven by ongoing compliance expenses associated with maintaining ASX listing requirements.
Payments to related parties, including director fees and consulting, amounted to $54,000 during the quarter. There were no reported cash flows from financing or investing activities, indicating the company is currently funding operations through existing cash reserves.
Operational Implications and Next Steps
The expanded preclinical program underscores Invex’s commitment to deepening its understanding of Exenatide’s role in neurological conditions linked to raised intracranial pressure and Alzheimer’s disease. The focus on ferroptosis and combination therapies could differentiate Invex’s approach from current standards of care, though clinical validation remains pending.
With cash reserves sufficient to sustain operations for the near term, investors will be watching for data releases from the Tessara collaboration and any indications of future capital raising to support ongoing research and potential clinical development phases.
Bottom Line?
Invex’s increased R&D investment signals a strategic push into Alzheimer’s research, but rising cash burn warrants attention to funding plans ahead.
Questions in the middle?
- How will results from the expanded Tessara program influence Invex’s clinical development timeline?
- What are the company’s plans to manage cash flow if operating outflows continue to increase?
- Could combination regimens with GLP-1 agonists and natural factors create a meaningful therapeutic advantage?